Skip to main content
Premium Trial:

Request an Annual Quote

Biosearch Acquires Rights to TurboFish Technology

NEW YORK (GenomeWeb News) – Biosearch Technologies today announced it has acquired the exclusive worldwide rights to the turboFISH technology.

As a result, the Petaluma, Calif.-based firm maintains exclusive access to continuing Stellaris RNA FISH-based inventions from Rutgers University, it said.

TurboFish is a method for rapid single molecule RNA FISH. In a statement, Marc Beal, director of corporate development and licensing at Biosearch, said, "Point-of-care, point-of-contact, hospital bedside, and immediate care facilities are now target markets for real-time gene expression analysis using turboFISH. Extending turboFISH into the [operating room] for intraoperative analysis may allow for real-time cancer diagnostics, eliminating the need, ambiguities, and procedure of formalin fixation and paraffin embedding tissues for days-later analysis."

Financial and other terms of the deal were not disclosed.

Biosearch recently acquired a majority stake in LightSpeed Genomics. The two firms are co-developing a gene expression platform, optimized to work on Stellaris RNA FISH assays for detecting and quantifying single molecular RNA targets within individual cells.

The Scan

Could Mix It Up

The US Food and Drug Administration is considering a plan that would allow for the mixing-and-matching of SARS-CoV-2 vaccines and boosters, the New York Times says.

Closest to the Dog

New Scientist reports that extinct Japanese wolf appears to be the closest known wild relative of dogs.

Offer to Come Back

The Knoxville News Sentinel reports that the University of Tennessee is offering Anming Hu, a professor who was acquitted of charges that he hid ties to China, his position back.

PNAS Papers on Myeloid Differentiation MicroRNAs, Urinary Exosomes, Maize Domestication

In PNAS this week: role of microRNAs in myeloid differentiation, exosomes in urine, and more.